Daré Bioscience’s (DARE) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a research note published on Thursday morning, Benzinga reports. They currently have a $12.00 price objective on the biotechnology company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.

Daré Bioscience Trading Up 0.3 %

NASDAQ DARE traded up $0.01 on Thursday, reaching $3.51. 5,203 shares of the company were exchanged, compared to its average volume of 45,821. Daré Bioscience has a fifty-two week low of $3.05 and a fifty-two week high of $7.56. The business’s fifty day moving average price is $3.41 and its 200 day moving average price is $3.98. The stock has a market capitalization of $29.56 million, a P/E ratio of -0.91 and a beta of 1.39.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $2.09. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.60 million. Equities research analysts forecast that Daré Bioscience will post -0.27 earnings per share for the current year.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC grew its position in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the SEC. Institutional investors own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.